Covance Blog
Potency evaluation, achieved through potency assays, is essential to transition an advanced therapy medicinal product or ATMP (also known as cell and gene therapy) through pivotal clinical stages to final market authorization. However, potency is a difficult parameter to assess for ATMPs, so it is important to start developing these …
Our “Meet Me in 5” series covers 5 people, topics or questions to illustrate how our business nurtures exceptional people, provides an energizing purpose and enables extraordinary potential in its employees’ careers. Every day counts in the fight against the COVID-19 pandemic. That’s why Covance, LabCorp’s drug development business, was …
In vivo respiratory disease models are valuable in the identification of potential medications targeted at treating human respiratory diseases. Common respiratory diseases include lung fibrosis or the emerging COVID-19, where highly efficacious treatments are limited and where in vivo disease models can help to screen for potential new treatments. In …
One hundred years ago, as women gained the right to vote in the United States, building on the progress of women’s movements around the world, women’s rights leader Alice Paul said: “I always feel the movement is a sort of mosaic. Each of us puts in one little stone, and …
Clinical trial sponsors need the ability to monitor the health of their study or portfolio of studies on an ongoing basis. In times of crises, this becomes a challenging task, as the rapidly evolving situation might render standard reporting tools inadequate and outdated. The Xcellerate® technology suite has been developed …
Assessing in vitro steroidogenesis endpoints is an important early step in establishing the endocrine disruptor (ED) potential of your crop protection product. Many regulators worldwide now require this information as part of the registration and approval process; for example, in the E.U., the updated pesticide and biocide directives now requests …
Welcome to the Covance Decentralized Clinical Trials (DCTs) monthly blog. With patient-centric trial designs becoming a driving force in the drug development industry, we will be doing a series of monthly blogs that look back on recent events which give us insight into designing resilient clinical trials and ensuring study …
You and your team have been working hard to gain approval and successfully launch your device. However, you may be forgetting an important consideration for market success: reimbursement.
The purported benefits of decentralized clinical trials (DCT) include accelerated enrollment, reduced patient burden and improved retention rates, among other efficiencies. Incorporating virtual elements into the traditional trial model requires a clear vision for the technologies, platforms and other “site-less” elements that support these efforts; however, the potential challenges of …
Solutions to the current COVID-19 pandemic involve preventing coronavirus infection through vaccination and treating the severe clinical symptoms of the disease, including acute respiratory distress syndrome (ARDS). Establishing in vitro screening for potential treatments, though, can be challenging, due to the limited number of appropriate research models available, and the …
